Exagen Debt to Equity Ratio 2019-2025 | XGN
Current and historical debt to equity ratio values for Exagen (XGN) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Exagen debt/equity for the three months ending September 30, 2025 was 1.35.
| Exagen Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-09-30 | $0.05B | $0.02B | 2.46 |
| 2025-06-30 | $0.04B | $0.02B | 1.79 |
| 2025-03-31 | $0.03B | $0.01B | 5.29 |
| 2024-12-31 | $0.04B | $0.01B | 3.68 |
| 2024-09-30 | $0.03B | $0.01B | 2.39 |
| 2024-06-30 | $0.03B | $0.02B | 1.80 |
| 2024-03-31 | $0.03B | $0.02B | 1.54 |
| 2023-12-31 | $0.03B | $0.02B | 1.51 |
| 2023-09-30 | $0.03B | $0.03B | 1.22 |
| 2023-06-30 | $0.03B | $0.03B | 1.01 |
| 2023-03-31 | $0.04B | $0.04B | 1.21 |
| 2022-12-31 | $0.04B | $0.04B | 1.03 |
| 2022-09-30 | $0.05B | $0.06B | 0.81 |
| 2022-06-30 | $0.04B | $0.06B | 0.70 |
| 2022-03-31 | $0.05B | $0.08B | 0.60 |
| 2021-12-31 | $0.04B | $0.09B | 0.45 |
| 2021-09-30 | $0.04B | $0.09B | 0.41 |
| 2021-06-30 | $0.04B | $0.10B | 0.38 |
| 2021-03-31 | $0.04B | $0.10B | 0.36 |
| 2020-12-31 | $0.04B | $0.04B | 0.87 |
| 2020-09-30 | $0.04B | $0.04B | 0.80 |
| 2020-06-30 | $0.03B | $0.05B | 0.68 |
| 2020-03-31 | $0.03B | $0.05B | 0.68 |
| 2019-12-31 | $0.03B | $0.06B | 0.59 |
| 2019-09-30 | $0.03B | $0.06B | 0.58 |
| 2019-06-30 | $0.00B | $0.00B | 0.00 |
| 2019-03-31 | $0.00B | $0.00B | 0.00 |
| 2018-12-31 | $0.00B | 0.00 | |
| 2018-09-30 | $0.00B | $0.00B | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.106B | $0.056B |
| Exagen Inc. is engaged in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases. It developed and commercialises testing products under AVISE brand. Exagen Inc. is based in Vista, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $211.725B | 24.40 |
| EssilorLuxottica (ESLOY) | France | $146.103B | 0.00 |
| Stryker (SYK) | United States | $139.118B | 27.62 |
| Boston Scientific (BSX) | United States | $130.559B | 29.85 |
| Medtronic (MDT) | Ireland | $124.048B | 17.19 |
| Medline (MDLN) | United States | $57.961B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.907B | 0.00 |
| Agilent Technologies (A) | United States | $39.588B | 25.03 |
| ResMed (RMD) | United States | $37.591B | 26.02 |
| GE HealthCare Technologies (GEHC) | United States | $37.239B | 17.81 |
| Koninklijke Philips (PHG) | Netherlands | $28.483B | 18.60 |
| Terumo (TRUMY) | Japan | $20.476B | 23.05 |
| Insulet (PODD) | United States | $20.239B | 62.82 |
| Zimmer Biomet Holdings (ZBH) | United States | $17.303B | 10.79 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.893B | 0.00 |
| Baxter (BAX) | United States | $10.338B | 8.34 |
| Sunny Optical Technology (SNPTF) | China | $9.589B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.457B | 30.41 |
| Demant (WILYY) | Denmark | $7.372B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $4.261B | 12.98 |
| Envista Holdings (NVST) | United States | $4.150B | 23.81 |
| BillionToOne (BLLN) | United States | $4.061B | 0.00 |
| ICU Medical (ICUI) | United States | $3.855B | 24.48 |
| Haemonetics (HAE) | United States | $3.378B | 15.04 |
| Prestige Consumer Healthcare (PBH) | United States | $3.131B | 14.28 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.099B | 0.00 |
| QuidelOrtho (QDEL) | United States | $2.255B | 14.50 |
| Perrigo (PRGO) | Ireland | $2.068B | 5.18 |
| Neogen (NEOG) | United States | $2.012B | 44.05 |
| LeMaitre Vascular (LMAT) | United States | $2.002B | 40.31 |
| AtriCure (ATRC) | United States | $1.942B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.805B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.678B | 73.55 |
| Phibro Animal Health (PAHC) | United States | $1.665B | 16.63 |
| Lumexa Imaging Holdings (LMRI) | United States | $1.471B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.437B | 20.80 |
| Kestra Medical Technologies (KMTS) | United States | $1.333B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.176B | 348.86 |
| Capricor Therapeutics (CAPR) | United States | $1.113B | 0.00 |
| Tilray Brands (TLRY) | Canada | $1.062B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.002B | 0.00 |
| InMode (INMD) | Israel | $0.881B | 9.96 |
| Valneva SE (VALN) | France | $0.867B | 0.00 |
| Omeros (OMER) | United States | $0.852B | 0.00 |
| CeriBell (CBLL) | United States | $0.814B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.578B | 15.67 |
| Cerus (CERS) | United States | $0.499B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.479B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.458B | 0.00 |
| Brainsway (BWAY) | Israel | $0.454B | 77.27 |
| Canopy Growth (CGC) | Canada | $0.438B | 0.00 |
| Quanterix (QTRX) | United States | $0.346B | 0.00 |
| Evolus (EOLS) | United States | $0.337B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.309B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.279B | 22.21 |
| TriSalus Life Sciences (TLSI) | United States | $0.276B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.240B | 141.00 |
| TerrAscend (TSNDF) | Canada | $0.239B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.232B | 0.00 |
| High Tide (HITI) | Canada | $0.224B | 0.00 |
| Organigram Global (OGI) | Canada | $0.218B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Sanara MedTech (SMTI) | United States | $0.203B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.196B | 17.27 |
| Accendra Health (ACH) | United States | $0.195B | 1.95 |
| OraSure Technologies (OSUR) | United States | $0.193B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.192B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.158B | 0.00 |
| Apyx Medical (APYX) | United States | $0.153B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.149B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.146B | 0.00 |
| Fonar (FONR) | United States | $0.116B | 16.79 |
| Jushi Holdings (JUSHF) | United States | $0.114B | 0.00 |
| MacroGenics (MGNX) | United States | $0.109B | 0.00 |
| Biote (BTMD) | United States | $0.106B | 4.64 |
| Sharps Technology (STSS) | United States | $0.069B | 0.00 |
| ImmuCell (ICCC) | United States | $0.058B | 24.46 |
| Nephros (NEPH) | United States | $0.048B | 34.46 |
| Cytosorbents (CTSO) | United States | $0.044B | 0.00 |
| Veru (VERU) | United States | $0.043B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.038B | 0.00 |
| Modular Medical (MODD) | United States | $0.037B | 0.00 |
| United-Guardian (UG) | United States | $0.031B | 15.67 |
| Jin Medical (ZJYL) | China | $0.024B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.023B | 0.00 |
| Bonk (BNKK) | United States | $0.018B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.015B | 0.00 |
| INLIF (INLF) | China | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.008B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.007B | 0.00 |
| Flora Growth (FLGC) | United States | $0.007B | 0.00 |
| Agape ATP (ATPC) | $0.004B | 0.00 | |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.000B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |